Press Releases2019-02-14T10:57:14-06:00

Press Releases

ELIAS Animal Health Cancer Immunotherapy Selected for State of the Art Presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical [...]

February 12th, 2018|

ELIAS Animal Health Adds Clinical Trial Site for ECI™ for the Treatment of Canine Osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal [...]

November 15th, 2016|

ELIAS Animal Health Announces First Patient Enrolled in Clinical Trial for ECI™ for the Treatment of Canine B-Cell Lymphoma

Olathe, Kan., Aug. 24, 2016 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive cancers to chemotherapy, permanent cures in dogs are extremely rare and remissions are short-lived. There is a need for safer, more effective treatments for this disease. The objective of this clinical trial is [...]

August 24th, 2016|